Text

The EBMT/EHA CAR-T Cell Handbook

---

Chimeric antigen receptor T cell therapy (CAR-T) is a new class of medicinal products that are genetically engineered from T cells. It is expected that other forms of
Immune Effector Cells-based therapies will soon reach the market, manufactured
from other subsets of immune cells, and engineered through other technologies than
currently used defective retroviral or lentiviral vectors. Cell-based immunotherapies
add to the broader feld of immunotherapies, now populated with monoclonal antibodies including immune checkpoint inhibitors, immune-conjugates, and bi- and
tri-specifc antibodies. Approximately 30 years after the frst publications reporting
on the development of genetically engineered T cells, expression of a frst generation chimeric antigen receptor (CAR), and the demonstration of its capability to
recognize antigens in the absence of MHC presentation in the 1980s, the frst commercially available CAR-T cell medicinal products were approved by the FDA and
later by the EMA for the treatment of relapsed/refractory diffuse large B cell lymphoma and relapsed/refractory acute lymphoblastic leukemia.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: Springer Cham., 2022

Collation

X, 237

Language

English

ISBN/ISSN

9783030943530

Classification

-

Content Type

-

Media Type

computer

Carrier Type

online resource

Edition

-

Subject(s)

The EBMT
EHA CAR
T Cell Handbook

Specific Detail Info

-

Statement of Responsibility

Curaj Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele

Other Information

Cataloger

angga

Source

-

Validator

-

Digital Object Identifier (DOI)

https://link.springer.com/book/10.1007/978-3-030-94353-0

Journal Volume

-

Journal Issue

-

Subtitle

-

Parallel Title

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment